{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:42:38Z","timestamp":1790322158776,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","id.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.idc.2014.05.002","type":"journal-article","created":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T08:01:15Z","timestamp":1409212875000},"page":"501-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Update on Opportunistic Infections in the Era of Effective Antiretroviral Therapy"],"prefix":"10.1016","volume":"28","author":[{"given":"Brian C.","family":"Zanoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh T.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2014.05.002_bib1","first-page":"869841","article-title":"CD4 cell counts at HIV diagnosis among HIV outpatient study participants, 2000\u20132009","volume":"2012","author":"Buchacz","year":"2012","journal-title":"AIDS Res Treat"},{"issue":"7","key":"10.1016\/j.idc.2014.05.002_bib2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/cid\/cit423","article-title":"The incidence of AIDS-defining illnesses at a current CD4 count\u00a0>\/= 200 cells\/muL in the post-combination antiretroviral therapy era","volume":"57","author":"Mocroft","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2014.05.002_bib3","author":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents","year":"2013"},{"issue":"22","key":"10.1016\/j.idc.2014.05.002_bib4","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1001\/archinte.167.22.2443","article-title":"Trends in tuberculosis\/human immunodeficiency virus comorbidity, United States, 1993-2004","volume":"167","author":"Albalak","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.idc.2014.05.002_bib5","series-title":"Reported Tuberculosis in the United States, 2012","author":"Center for Disease Control","year":"2013"},{"issue":"9364","key":"10.1016\/j.idc.2014.05.002_bib6","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S0140-6736(03)12950-9","article-title":"Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak","volume":"361","author":"Ewer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2014.05.002_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2334-9-15","article-title":"Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals","volume":"9","author":"Talati","year":"2009","journal-title":"BMC Infect Dis"},{"issue":"RR-5","key":"10.1016\/j.idc.2014.05.002_bib8","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"10.1016\/j.idc.2014.05.002_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","article-title":"Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Rangaka","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"4 Pt 2","key":"10.1016\/j.idc.2014.05.002_bib10","first-page":"S221","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.idc.2014.05.002_bib11","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"issue":"2","key":"10.1016\/j.idc.2014.05.002_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.idc.2014.05.002_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"10.1016\/j.idc.2014.05.002_bib14","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.idc.2014.05.002_bib15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1164\/rccm.200905-0692OC","article-title":"Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus","volume":"180","author":"Monkongdee","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.idc.2014.05.002_bib16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa0907847","article-title":"Rapid molecular detection of tuberculosis and rifampin resistance","volume":"363","author":"Boehme","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.idc.2014.05.002_bib17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1164\/rccm.200709-1436OC","article-title":"Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa","volume":"177","author":"Barnard","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.idc.2014.05.002_bib18","first-page":"580","article-title":"Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB\/RIF assay: a meta-analysis","volume":"64","author":"Chang","year":"2012","journal-title":"J\u00a0Infect"},{"issue":"11","key":"10.1016\/j.idc.2014.05.002_bib19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s10096-013-1890-0","article-title":"Diagnostic accuracy and effectiveness of the Xpert MTB\/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis","volume":"32","author":"Van Rie","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2014.05.002_bib20","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/JCM.02319-10","article-title":"Xpert MTB\/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?","volume":"49","author":"Vadwai","year":"2011","journal-title":"J\u00a0Clin Microbiol"},{"issue":"9","key":"10.1016\/j.idc.2014.05.002_bib21","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.5588\/ijtld.13.0178","article-title":"Xpert(R) MTB\/RIF in pleural fluid for the diagnosis of tuberculosis","volume":"17","author":"Porcel","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.idc.2014.05.002_bib22","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1128\/JCM.02268-10","article-title":"Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB\/RIF system","volume":"49","author":"Hillemann","year":"2011","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.idc.2014.05.002_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2334-12-47","article-title":"Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria","volume":"12","author":"Wood","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.idc.2014.05.002_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2334-12-103","article-title":"Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review","volume":"12","author":"Lawn","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2014.05.002_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1473-3099(11)70251-1","article-title":"Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study","volume":"12","author":"Lawn","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2014.05.002_bib26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2014.05.002_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5588\/ijtld.13.0627","article-title":"Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial","volume":"18","author":"Padayatchi","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"16","key":"10.1016\/j.idc.2014.05.002_bib28","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.idc.2014.05.002_bib29","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.idc.2014.05.002_bib30","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2014.05.002_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QAI.0000000000000030","article-title":"Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity and implications for HIV-TB programs","volume":"65","author":"Luetkemeyer","year":"2014","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2014.05.002_bib32","series-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","author":"WHO","year":"2013"},{"issue":"11","key":"10.1016\/j.idc.2014.05.002_bib33","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)\u2013associated tuberculous meningitis","volume":"52","author":"Torok","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2014.05.002_bib34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cid\/cir447","article-title":"Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial","volume":"53","author":"Swaminathan","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2014.05.002_bib35","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy","volume":"300","author":"Boulle","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.idc.2014.05.002_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.aids.0000196181.18916.9b","article-title":"Efavirenz 600 mg\/day versus efavirenz 800 mg\/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results","volume":"20","author":"Manosuthi","year":"2006","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.idc.2014.05.002_bib37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/cit246","article-title":"Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study","volume":"57","author":"Luetkemeyer","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2014.05.002_bib38","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/QAD.0b013e3282faa71e","article-title":"High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir\/ritonavir tablets","volume":"22","author":"Nijland","year":"2008","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.idc.2014.05.002_bib39","doi-asserted-by":"crossref","first-page":"e44793","DOI":"10.1371\/journal.pone.0044793","article-title":"Coadministration of lopinavir\/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa","volume":"7","author":"Murphy","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.idc.2014.05.002_bib40","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1128\/AAC.01468-08","article-title":"Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir","volume":"53","author":"Wenning","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2014.05.002_bib41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(14)70711-X","article-title":"ANRS 12 180 Reflate TB study group. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial","volume":"14","author":"Grinsztejn","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2014.05.002_bib42","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/0091270010375959","article-title":"Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in\u00a0vitro\/in\u00a0vivo correlation","volume":"51","author":"Brainard","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.idc.2014.05.002_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","article-title":"Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","volume":"62","author":"Dooley","year":"2013","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.idc.2014.05.002_bib44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.idc.2014.05.002_bib45","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1097\/QAI.0b013e31824c837e","article-title":"Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care","volume":"59","author":"Rajasingham","year":"2012","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.idc.2014.05.002_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3201\/eid2001.130906","article-title":"Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast","volume":"20","author":"Boulware","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2014.05.002_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/cid\/cit641","article-title":"Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid","volume":"58","author":"Kabanda","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2014.05.002_bib48","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/cid\/cir613","article-title":"Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis","volume":"53","author":"Jarvis","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2014.05.002_bib49","series-title":"Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults","author":"World Health Organization","year":"2011"},{"issue":"3","key":"10.1016\/j.idc.2014.05.002_bib50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11904-012-0127-7","article-title":"New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis","volume":"9","author":"Jackson","year":"2012","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"10.1016\/j.idc.2014.05.002_bib51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.1016\/j.idc.2014.05.002_bib52","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2014.05.002_bib53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety","volume":"51","author":"Hamill","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2014.05.002_bib54","doi-asserted-by":"crossref","first-page":"e5575","DOI":"10.1371\/journal.pone.0005575","article-title":"Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial","volume":"4","author":"Zolopa","year":"2009","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.idc.2014.05.002_bib55","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1086\/652652","article-title":"Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa","volume":"50","author":"Makadzange","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"26","key":"10.1016\/j.idc.2014.05.002_bib56","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","article-title":"Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis","volume":"370","author":"Boulware","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.idc.2014.05.002_bib57","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1473-3099(10)70170-5","article-title":"Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions","volume":"10","author":"Haddow","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2014.05.002_bib58","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1086\/428618","article-title":"The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy","volume":"40","author":"Shelburne","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2014.05.002_bib59","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/QAI.0b013e3181a56f2e","article-title":"Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study","volume":"51","author":"Bicanic","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"13","key":"10.1016\/j.idc.2014.05.002_bib60","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1097\/QAD.0b013e3283614a8d","article-title":"Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome","volume":"27","author":"Chang","year":"2013","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.idc.2014.05.002_bib61","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1086\/655785","article-title":"Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome","volume":"202","author":"Boulware","year":"2010","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2014.05.002_bib62","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ana.10827","article-title":"Changing incidence of central nervous system diseases in the EuroSIDA cohort","volume":"55","author":"d'Arminio Monforte","year":"2004","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.idc.2014.05.002_bib63","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1212\/WNL.0b013e31820c3089","article-title":"Survival after neuroAIDS: association with antiretroviral CNS penetration-effectiveness score","volume":"76","author":"Lanoy","year":"2011","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.idc.2014.05.002_bib64","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1473-3099(09)70226-9","article-title":"Progressive multifocal leukoencephalopathy in HIV-1 infection","volume":"9","author":"Cinque","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2014.05.002_bib65","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.idc.2014.05.002_bib66","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/WNL.0b013e31820d8b0b","article-title":"Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease","volume":"76","author":"Garvey","year":"2011","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.idc.2014.05.002_bib67","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","article-title":"Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team","volume":"338","author":"Hall","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.idc.2014.05.002_bib68","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/QAD.0b013e32830a5043","article-title":"Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis","volume":"22","author":"De Luca","year":"2008","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.idc.2014.05.002_bib69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","article-title":"A\u00a0study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes","volume":"19","author":"Clifford","year":"2013","journal-title":"J\u00a0Neurovirol"},{"issue":"1\u20132","key":"10.1016\/j.idc.2014.05.002_bib70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virusres.2007.11.002","article-title":"Interferon beta1-a and selective anti-5HT(2a) receptor antagonists inhibit infection of human glial cells by JC virus","volume":"132","author":"O'Hara","year":"2008","journal-title":"Virus Res"},{"issue":"6","key":"10.1016\/j.idc.2014.05.002_bib71","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2146\/ajhp110392","article-title":"Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus","volume":"69","author":"Moenster","year":"2012","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.idc.2014.05.002_bib72","first-page":"35","article-title":"Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy","volume":"17","author":"Lanzafame","year":"2009","journal-title":"Infez Med"},{"issue":"1","key":"10.1016\/j.idc.2014.05.002_bib73","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12185-013-1471-0","article-title":"Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation","volume":"99","author":"Yoshida","year":"2014","journal-title":"Int J Hematol"},{"issue":"17","key":"10.1016\/j.idc.2014.05.002_bib74","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","article-title":"PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids","volume":"72","author":"Tan","year":"2009","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.idc.2014.05.002_bib75","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1304828","article-title":"Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome","volume":"370","author":"Giacomini","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2014.05.002_bib76","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1086\/515658","article-title":"Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis","volume":"178","author":"Kaplan","year":"1998","journal-title":"J\u00a0Infect Dis"},{"issue":"14","key":"10.1016\/j.idc.2014.05.002_bib77","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1097\/00002030-200109280-00012","article-title":"Adult, adolescent spectrum of HIVDPI. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents","volume":"15","author":"Kaplan","year":"2001","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.idc.2014.05.002_bib78","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1378\/chest.120.6.1888","article-title":"Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy","volume":"120","author":"Wolff","year":"2001","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.idc.2014.05.002_bib79","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/cid\/cir996","article-title":"A\u00a0cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii","volume":"54","author":"Le Gal","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2014.05.002_bib80","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3201\/eid1805.111432","article-title":"Possible nosocomial transmission of Pneumocystis jirovecii","volume":"18","author":"Damiani","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2014.05.002_bib81","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1378\/chest.93.5.987","article-title":"Elevated lactate dehydrogenase values in patients with Pneumocystis carinii pneumonia","volume":"93","author":"Smith","year":"1988","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.idc.2014.05.002_bib82","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1086\/588564","article-title":"Use of a serum beta-glucan assay for diagnosis of HIV-related Pneumocystis jirovecii pneumonia in patients with negative microscopic examination results","volume":"46","author":"Pisculli","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2014.05.002_bib83","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cir335","article-title":"Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia","volume":"53","author":"Sax","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2014.05.002_bib84","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/QAD.0b013e32835cb646","article-title":"Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms","volume":"27","author":"Wood","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2014.05.002_bib85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-9378-4-7","article-title":"The evolving definition of carcinogenic human papillomavirus","volume":"4","author":"Castle","year":"2009","journal-title":"Infect Agents Canc"},{"issue":"9686","key":"10.1016\/j.idc.2014.05.002_bib86","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.idc.2014.05.002_bib87","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.idc.2014.05.002_bib88","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2014.05.002_bib89","series-title":"Recommended adult immunization schedule: United States","author":"Center for Disease Control","year":"2014"},{"issue":"5","key":"10.1016\/j.idc.2014.05.002_bib90","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/cid\/cit319","article-title":"Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women","volume":"57","author":"Kahn","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2014.05.002_bib91","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciu238","article-title":"Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women","author":"Kojic","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2014.05.002_bib92","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1086\/656320","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men","volume":"202","author":"Wilkin","year":"2010","journal-title":"J\u00a0Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2014.05.002_bib93","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/infdis\/166.5.1153","article-title":"Herpes zoster and human immunodeficiency virus infection","volume":"166","author":"Buchbinder","year":"1992","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2014.05.002_bib94","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1086\/315146","article-title":"Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997. District of Columbia Gay Cohort Study. Multicenter Hemophilia Cohort Study","volume":"180","author":"Engels","year":"1999","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2014.05.002_bib95","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.qai.0000178408.62675.b0","article-title":"The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era","volume":"40","author":"Gebo","year":"2005","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.idc.2014.05.002_bib96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00126334-200501010-00020","article-title":"The incidence of herpes zoster is less likely than other opportunistic infections to be reduced by highly active antiretroviral therapy","volume":"38","author":"Vanhems","year":"2005","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1016\/j.idc.2014.05.002_bib97","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1086\/652798","article-title":"Effectiveness of varicella vaccine in children infected with HIV","volume":"201","author":"Son","year":"2010","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2014.05.002_bib98","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/INF.0b013e3181fe0868","article-title":"The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children","volume":"30","author":"Taweesith","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.idc.2014.05.002_bib99","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cit665","article-title":"Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America","volume":"58","author":"Aberg","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2014.05.002_bib100","unstructured":"Benson C, Hua L, Andersen J, et\u00a0al. ZOSTAVAX is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo-controlled trial. Presented at the 19th Conference on Retroviruses and Opportunistic Infections. Abstract #96. Seattle (WA), March 5\u20138, 2012."}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552014000312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552014000312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T02:58:13Z","timestamp":1538276293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552014000312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0891552014000312"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2014.05.002","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Opportunistic Infections in the Era of Effective Antiretroviral Therapy","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2014.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}